Jorge Armando Ortiz Ramírez

Prof. Dr. Jorge Armando Ortiz Ramírez

Medical Sciences, Universidad de Guanajuato, Guanajuato City, Mexico
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Gustavo Alexis Nino-VegaGustavo Alexis Nino-Vega
Gustavo Alexis Nino-Vega
Jorge Armando Ortiz RamírezJorge Armando Ortiz Ramírez
Jorge Armando Ortiz Ramírez
Everardo López-RomeroEverardo López-Romero
Everardo López-Romero
The increase in multidrug-resistant organisms worldwide is a major public health threat driven by antibiotic overuse, horizontal gene transfer (HGT), environmental drivers, and deficient infection control in hospitals. In this article, we discuss these factors and summarize the new drugs and treatment strategies suggested to combat the increasing challenges of multidrug-resistant (MDR) bacteria. New treatments recently developed involve targeting key processes involved in bacterial growth, such as riboswitches and proteolysis, and combination therapies to improve efficacy and minimize adverse effects. It also tackles the challenges of the Gram-negative bacterial outer membrane, stressing that novel strategies are needed to evade permeability barriers, efflux pumps, and resistance mechanisms. Other approaches, including phage therapy, AMPs, and AI in drug discovery, are also discussed as potential alternatives. Finally, this review points out the urgency for continued research and development (R&D), industry–academic partnerships, and financial engines to ensure that MDR microbes do not exceed the value of antibacterial therapies.

23 September 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
Jorge Armando Ortiz RamírezJorge Armando Ortiz Ramírez
Jorge Armando Ortiz Ramírez
MCMayra Cuéllar-Cruz
Mayra Cuéllar-Cruz
Everardo López-RomeroEverardo López-Romero
Everardo López-Romero
The cell wall (CW) of fungi exhibits a complex structure and a characteristic chemical composition consisting almost entirely of interacting crystalline and amorphous polysaccharides. These are synthesized by a number of sugar polymerases and depolymerases encoded by a high proportion of the fungal genome (for instance, 20% inSaccharomyces cerevisiae). These enzymes act in an exquisitely coordinated process to assemble the tridimensional and the functional structure of the wall. Apart from playing a critical role in morphogenesis, cell protection, viability and pathogenesis, the CW represents a potential target for antifungals as most of its constituents do not exist in humans. Chitin, β-glucans and cellulose are the most frequent crystalline polymers found in the fungal CW. The hexosamine biosynthesis pathway (HBP) is critical for CW elaboration. Also known as the Leloir pathway, this pathway ends with the formation of UDP-N-GlcNAc after four enzymatic steps that start with fructose-6-phosphate and L-glutamine in a short deviation of glycolysis. This activated aminosugar is used for the synthesis of a large variety of biomacromolecules in a vast number of organisms including bacteria, fungi, insects, crustaceans and mammalian cells. The first reaction of the HBP is catalyzed by GlcN-6-P synthase (L-glutamine:D-fructose-6-phosphate amidotransferase; EC 2.6.1.16), a critical enzyme that has been considered as a potential target for antifungals. The enzyme regulates the amount of cell UDP-N-GlcNAc and in eukaryotes is feedback inhibited by the activated aminosugar and other factors. The native and recombinant forms of GlcN-6-P synthase has been purified and characterized from both prokaryotic and eukaryotic organisms and demonstrated its critical role in CW remodeling and morphogenesis after exposure of some fungi to agents that stress the cell surface by interacting with wall polymers. This review deals with some of the cell compensatory responses of fungi to wall damage induced by Congo Red and Calcofluor White.

6 July 2023 in Medical Mycology
Verified
Journal Article
Closed access
PDF file
FTFátima Tornero-Gutiérrez
Fátima Tornero-Gutiérrez
Jorge Armando Ortiz RamírezJorge Armando Ortiz Ramírez
Jorge Armando Ortiz Ramírez
ELEverardo López-Romero
Everardo López-Romero
Mayra Cuéllar-CruzMayra Cuéllar-Cruz
Mayra Cuéllar-Cruz
The species of the Candida genus are opportunistic pathogenic fungi found in humans and are responsible for approximately 80% of worldwide fungal infections. Aimed to diminish and preventing Candida adhesion to cells or implanted devices in the human host, a large diversity of materials has been developed and functionalized that have attracted much interest. Furthermore, these materials have been focused almost exclusively on Candida albicans, followed by Candida glabrata, Candida parapsilosis, and Candida tropicalis. Although an important diversity of materials have been synthesized to prevent adherence and formation of biofilms by Candida species, it is however important to evaluate the capacity of each material in terms of its property to diminish the adherence of Candida. These materials are discussed in this review. Candida species are opportunistic pathogenic fungi of humans. To reduce and preventing their ability to adhere to cells and form biofilms, a large diversity of materials, focused almost exclusively on pathogenic species of Candida has been developed and functionalized.

3 March 2021 in Antonie van Leeuwenhoek
Verified
Journal Article
Closed access
PDF file
Jorge Armando Ortiz RamírezJorge Armando Ortiz Ramírez
Jorge Armando Ortiz Ramírez
Mayra Cuéllar-CruzMayra Cuéllar-Cruz
Mayra Cuéllar-Cruz
Everardo López-RomeroEverardo López-Romero
Everardo López-Romero

12 September 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Jorge Armando Ortiz RamírezJorge Armando Ortiz Ramírez
Jorge Armando Ortiz Ramírez
Mayra Cuéllar-CruzMayra Cuéllar-Cruz
Mayra Cuéllar-Cruz
JVJulio César Villagómez-Castro
Julio César Villagómez-Castro
Everardo López-RomeroEverardo López-Romero
Everardo López-Romero
Glycoside hydrolases (GHs) are enzymes that participate in many biological processes of fungi and other organisms by hydrolyzing glycosidic linkages in glycosides. They play fundamental roles in the degradation of carbohydrates and the assembly of glycoproteins and are important subjects of studies in molecular biology and biochemistry. Based on amino acid sequence similarities and 3-dimensional structures in the carbohydrate-active enzyme (CAZy), they have been classified in 171 families. Members of some of these families also exhibit the activity of trans-glycosydase or glycosyl transferase (GT), i.e., they create a new glycosidic bond in a substrate instead of breaking it. Fungal glycosidases are important for virulence by aiding tissue adhesion and colonization, nutrition, immune evasion, biofilm formation, toxin release, and antibiotic resistance. Here, we review fungal glycosidases with a particular emphasis on Sporothrix species and C. albicans, two well-recognized human pathogens. Covered issues include a brief account of Sporothrix, sporotrichosis, the different types of glycosidases, their substrates, and mechanism of action, recent advances in their identification and characterization, their potential biotechnological applications, and the limitations and challenges of their study given the rather poor available information.

4 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Gustavo Alexis Nino-VegaGustavo Alexis Nino-Vega
Gustavo Alexis Nino-Vega
Jorge Armando Ortiz RamírezJorge Armando Ortiz Ramírez
Jorge Armando Ortiz Ramírez
Everardo López-RomeroEverardo López-Romero
Everardo López-Romero
The increase of multi-drug resistant organisms worldwide is a major public health threat driven by antibiotic overuse, horizontal gene transfer (HGT), environmental drivers, and deficient infection control in hospitals. In this article, we discuss these factors and summarize the new drugs and treatment strategies suggested to combat the increasing challenges of multidrug-resistant (MDR) bacteria. New treatments recently developed involve targeting key processes involved in bacterial growth, such as riboswitches and proteolysis, and combination therapies to improve efficacy and minimize adverse effects. It also tackles the challenges of the Gram-negative bacterial outer membrane, stressing that novel strategies are needed to evade permeability barriers, efflux pumps, and resistance mechanisms. Other approaches, including phage therapy, AMPs, and AI in drug discovery, are also discussed as potential alternatives. Finally, this review points out the urgency for continued research and development (R&D), industry‐academic partnerships, and financial engines to ensure that MDR microbes do not exceed the value of antibacterial therapies.